PT-141 (Bremelanotide) vs Epithalamin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Epithalamin
Epithalamin is a natural peptide extract from the pineal gland. It is the precursor compound from which the synthetic Epitalon was derived. Known for anti-aging and telomerase-activating properties.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Epithalamin |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Similar to Epitalon, it stimulates telomerase production and may help maintain telomere length. Also regulates melatonin synthesis and circadian rhythms. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Research dosing: 10-20mg daily for 10-20 day cycles. Often administered 1-3 times per year in long-term protocols. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Intramuscular or subcutaneous injection. Natural extract may have more variable composition than synthetic Epitalon. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Generally well-tolerated. May affect sleep patterns. Less characterized than synthetic Epitalon. |
| Best For |